Neurocrine Biosciences Files 8-K

TL;DR

NBIX filed an 8-K, but no details yet.

AI Summary

Neurocrine Biosciences, Inc. filed an 8-K on December 20, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.

Why It Matters

This 8-K filing indicates that Neurocrine Biosciences has reported an event requiring immediate disclosure to the SEC, though the specifics are not detailed in this summary.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not contain information that inherently poses a risk.

Key Players & Entities

• NEUROCRINE BIOSCIENCES, INC. (company) — Registrant
• 0000914475-24-000229 (filing_id) — Accession Number
• December 20, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar
• $38,333 — Y in the United States of approximately $38,333 for a 30-day supply. For pediatric pati
• $19,167 — r a 30-day supply will be approximately $19,167. The Company expects 90% of patients wi
• $12 — f patients will have a monthly copay of $12 or less. Forward-Looking Statements I

Filing Documents

• nbix-20241220.htm (8-K) — 25KB
• nbix20241220-exhibit991.htm (EX-99.1) — 27KB
• nbix-20241220_g1.jpg (GRAPHIC) — 18KB
• 0000914475-24-000229.txt ( ) — 230KB
• nbix-20241220.xsd (EX-101.SCH) — 2KB
• nbix-20241220_lab.xml (EX-101.LAB) — 21KB
• nbix-20241220_pre.xml (EX-101.PRE) — 12KB
• nbix-20241220_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On December 20, 2024, Neurocrine Biosciences, Inc. ("Neurocrine Biosciences" or the "Company") issued a press release announcing that CRENESSITY TM (crinecerfont) capsules and oral solution are now available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company has established a wholesale acquisition cost for CRENESSITY in the United States of approximately $38,333 for a 30-day supply. For pediatric patients weighing less than 20 kilograms, the wholesale acquisition cost for a 30-day supply will be approximately $19,167. The Company expects 90% of patients will have a monthly copay of $12 or less.

Forward-Looking Statements

Forward-Looking Statements In addition to historical facts, this Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency; the ability of the Company to ensure patients have access to CRENESSITY; and the Company's expectations regarding coverage and reimbursement from third-party payors for CRENESSITY. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Neurocrine Biosciences, Inc. on December 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: December 20, 2024 /s/ Darin M. Lippoldt Darin M. Lippoldt Chief Legal Officer